Regeneron’s rare disease drug succeeds in Phase 3 studynews2025-08-26T15:52:53+00:00August 26th, 2025|Endpoints News|
Novartis pays $30M to Leqembi creator for access to blood-brain barrier technews2025-08-26T15:05:22+00:00August 26th, 2025|Endpoints News|
Incannex’s stock rallies on anxiety disorder data; Appia Bio closes its doorsnews2025-08-26T14:51:38+00:00August 26th, 2025|Endpoints News|
Why Cheryl Pegus joined weight loss startup FlyteHealthnews2025-08-26T13:25:09+00:00August 26th, 2025|Endpoints News|
Neuro biotech Leal Therapeutics raises $30M Series Anews2025-08-26T11:00:39+00:00August 26th, 2025|Endpoints News|
Lilly plans GLP-1 pill filing after trial success in obesity and diabetesnews2025-08-26T10:45:53+00:00August 26th, 2025|Endpoints News|
BARDA awards nearly $20M to flu vaccine maker Osivaxnews2025-08-26T09:00:23+00:00August 26th, 2025|Endpoints News|
HHS winds down decades-old pediatric brain cancer collaborationnews2025-08-25T19:39:28+00:00August 25th, 2025|Endpoints News|
Overall survival in cancer drug trials: New FDA draft guidance sets the barnews2025-08-25T18:20:37+00:00August 25th, 2025|Endpoints News|
FDA begins publishing adverse event data on a daily basisnews2025-08-25T17:55:29+00:00August 25th, 2025|Endpoints News|
